CIALIS® (tadalafil) for HCPs: Official Site

Important Safety Information for CIALIS ^® (tadalafil)

Contraindications

Nitrates: CIALIS should not be used in patients using any form of organic nitrate, either regularly and/or intermittently, as the combination could cause a sudden, unsafe drop in blood pressure.

Hypersensitivity reactions: CIALIS is contraindicated in patients with a known serious hypersensitivity to CIALIS or ADCIRCA^™ (tadalafil). Hypersensitivity reactions have been reported, including Stevens-Johnson syndrome and exfoliative dermatitis.

Warnings and Precautions

Cardiovascular: Physicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity. Treatments for erectile dysfunction, including CIALIS, should not be used in men for whom sexual activity is inadvisable as a result of their underlying cardiovascular status. Patients who experience symptoms upon initiation of sexual activity should be advised to refrain from further sexual activity and seek immediate medical attention. PDE5 inhibitors, including CIALIS, are mild systemic vasodilators. While this effect should not be of consequence in most patients, physicians should consider this potential when prescribing CIALIS.

Patients with left ventricular outflow obstruction (e.g., aortic stenosis and idiopathic hypertrophic subaortic stenosis) can be sensitive to the action of vasodilators, including PDE5 inhibitors.

CIALIS was not studied and is not recommended in patients who have recently suffered a heart attack (within 90 days) or stroke (within 6 months), or patients with uncontrolled hypertension, hypotension, uncontrolled arrhythmias, heart failure (NYHA ≥ Class 2 in last 6 months), unstable angina or angina occurring during sexual activity.

Potential Drug Interactions: Due to potential increased blood-pressure-lowering effects, caution is advised when CIALIS is co-administered with alpha blockers, antihypertensives, and/or substantial consumption of alcohol (5 units or greater). CIALIS for once daily use provides continuous plasma tadalafil levels. Physicians should consider this when evaluating the potential for interactions.

Combination with other PDE5 inhibitors: CIALIS is also marketed as ADCIRCA for the treatment of pulmonary arterial hypertension. Do not take both CIALIS and ADCIRCA or other PDE5 inhibitors.

Potent inhibitors of CYP3A4: For patients taking potent inhibitors of CYP3A4, dose should be adjusted: CIALIS for use as needed: ≤10mg every 72 hours. CIALIS for once daily use: dose not to exceed 2.5 mg.

Special Populations: For patients with severe hepatic impairment use of CIALIS is not recommended. For patient with severe renal impairment CIALIS for daily use is not recommended. Additional dose adjustments may be required for mild and moderate renal and hepatic impairment or with other concomitant medications. See Dosing Guidelines and full Prescribing Information for complete dosing instructions.

Prolonged Erection: There have been rare reports of priapism with this class of compounds. Patients should be advised to seek immediate medical attention should this occur. Use CIALIS with caution in patients who have conditions that might predispose them to priapism.

Vision/Hearing: The following events have been reported in men taking PDE5 inhibitors including CIALIS: (1) sudden decrease or loss of vision in one or both eyes; (2) sudden loss or decrease in hearing, sometimes with ringing in the ears and dizziness. It is not possible to determine whether these events are related directly to the medicines, other health conditions, or to a combination of these. If a patient experiences a sudden decrease or loss in vision or hearing he should stop taking CIALIS, and call a healthcare provider right away.

Adverse Reactions

Most common adverse reactions (≥2%) include headache, dyspepsia, back pain, myalgia, nasal congestion, flushing, and pain in limb.

For more complete information see Important Safety Information and full Prescribing Information.

Prescribing Information \| Patient Information \| Important Safety Information
Site Map \| Contact Us \| Privacy Statement \| Terms of Use \| Copyright

©2009 Eli Lilly and Company. All Rights Reserved.
CIALIS^® is a registered trademark of Eli Lilly and Company. This site is intended for use by healthcare professionals in the United States only.
TD60468

Site Map